Bavituximab

Research use only, not for human use.

Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody targeting phosphatidylserine (PS) with vascular targeting and immunomodulatory properties, capable of reactivating anti-tumor immunity to inhibit tumor growth.

Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer.

Bavituximab binds to exposed phosphatidylserine (PS) molecules via the serum protein, β2-glycoprotein 1 (β2GP1).Bavituximab binds PS to induces antibody-dependent cellular cytotoxicity, resulting in tumor vessel destruction.Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) via 10 μM Sorafenib inducing exposure in HUVEC and bEnd.3 cells.

Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo.Animal Model:Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors Dosage:100 μg/mouse (Bavituximab/β2GP1) Administration:Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose)Result:Traced phosphatidylserine exposure in vivo in mice with tumors.

——

Others

Other Targets

Others

——

——

648904-28-3

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years